Immunotherapy Publications & Patents

• Research Home
>
• Laboratory Research
>
• Cancer Immunology Program
>
• Immunotherapy
>
• Immunotherapy Publications & Patents

Immunotherapy Publications & Patents - Research at Peter Mac

Recent Publications

Kershaw M.H., Westwood J.A., Parker L.L., Wang G., Eshhar Z., Mavroukakis S.A., White D.E., Wunderlich J.R., Yang J.C., Canevari S., Chen C.C., Rosenberg S.A., Hwu P. A Phase I Trial Utilizing Adoptive Transfer of Gene-Modified T Cells for Ovarian Cancer. Clinical Cancer Research 2006 Oct; 12:6106-6115. IF=6.2 (7) Teng M.W.L., Kershaw M.H., Jackson J.T., Smyth M.J., Darcy P.K.. Adoptive Transfer of Chimeric FceRI Gene-Modified Human T Cells for Cancer Immunotherapy. Hum Gene Ther. 2006 Oct 19 IF=4.5 (2) Murphy A., Westwood J.A., Brown L.E., Teng M.W.L., Moeller M., Xu Y., Smyth M.J., Hwu P., Darcy P.K. and Kershaw M.H.. Tumor inhibition in mice mediated by dual-specific T cells and influenza virus. Cancer Gene Therapy 2007 March; 14:499-508. IF=4.2 (0) Xu Y., Darcy P.K. and Kershaw M.H.. Tumor-specific dendritic cells generated by genetic redirection of Toll-like receptor signaling against the tumor-associated antigen, erbB2. Cancer Gene Therapy 2007, 14:773-780. IF=4.2 (0) Teng M.W.L., Westwood J.A., Darcy P.K., Sharkey J., Tsuji M., Porcelli S.A., Besra G., Godfrey D.I., Takeda K., Yagita H., Kershaw M.H. and Smyth M.J. Combined NKT cell-based immunotherapy eradicates established tumors in mice. Cancer Research 2007, 67:7495-7504.. IF=7.7 (0) Xu Y., Zhan Y., Lew A.M., Naik S.H. and Kershaw M.H. Differential development of murine dendritic cells by GM-CSF versus Flt3 ligand has implications for inflammation and trafficking. Journal of Immunology 2007. 179:7577-7584. IF=6.3 (0) Moeller M., Kershaw M.H., Cameron R., Westwood J.A., Trapani J.A., Smyth M.J. and Darcy P.K.. Sustained antigen-specific anti-tumor recall response mediated by transfer of both genetically modified CD4+ T helper 1 cells and CD8+ T cells. Cancer Research 2007. 67:11428-11437 IF=7.7 (0) Smyth, M. J., Teng, M. W. L., Sharkey, J., Westwood, J. A., Yagita, H., Takeda, K., Sivakumar, P., and Kershaw, M. H.: IL-21 enhances antibody-mediated tumor rejection. Cancer Res. 2008 68:3019-3025. IF=7.7 (0) Westwood J.A., Murray W.K., Trivett M., Shin A., Neeson P., MacGregor D.P., Haynes N.M., Trapani J.A., Mayura-Guru P., Fox S., Peinert S., Honemann D., Prince H.M., Ritchie D., Scott A.M., Smyth F.E., Smyth M.J., Darcy P.K. and Kershaw M.H.. Absence of retroviral vector-mediated transformation of gene-modified T cells after long-term engraftment in mice. Gene Therapy 2008 15:1056-1066. IF=4.8 (0). Williams BB, Wall M, Miao RY, Williams B, Bertoncello I, Kershaw MH, Mantamadiotis T, Haber M, Norris MD, Gautam A, Darcy PK, Ramsay RG. Induction of T cell-mediated immunity using a c-Myb DNA vaccine in a mouse model of colon cancer. Cancer Immunology, Immunotherapy. 2008 57:1635-1645. (IF = 4.3) Pegram HJ, Jackson JT, Smyth MJ, Darcy PK, Kershaw MH. Adoptive transfer of gene-modified primary NK cells can specifically inhibit tumor progression in vivo. J Immunol. 2008 181:3449-3455. IF=6.3(0) Radkevich-Brown O, Jacob J, Kershaw MH and Wei WZ. Genetic regulation of the response to Her-2 DNA vaccination in human Her-2 transgenic mice. Cancer Research. 2009 69(1):212-8. IF=7.7 Westwood JA, MurraY WK, Trivett M, Haynes NM, Solomon B, Mileshkin L, Ball D, Michael M, Burman A, Mayura-Guru P, Trapani JA, Peinert S, Hönemann D, Prince HM, Scott AM, Smyth MJ, Darcy PK and Kershaw MH. The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serum. J. Immunotherapy 2009 32:292-301. IF=4.8 Birkholz K, Hombach A, Krug C, Reuter S, Kershaw MH, Kämpgen E, Schuler G, Abken H, Schaft N, and Dörrie J. Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer. Gene Therapy (in press 2009). IF=4.8 Pegram HJ, Darcy PK and Kershaw MH. Bcl-2 overexpression and genetic manipulation of T cells provides tumor specificity and enhanced resistance to apoptosis in vitro. The Open Gene Therapy Journal 2009 2:29-37. Dworkin, S., Malaterre, J., Hollande, F., Darcy, P. K., Ramsay, R. G. and Mantamadiotis, T. cAMP response element binding protein is required for mouse neural progenitor cell survival and expansion. Stem Cells 27(6):1347-1357, 2009. Pegram, H. J., Kershaw, M. H. and Darcy, P. K. Genetic modification of NK cells for adoptive cellular immunotherapy. Immunotherapy, 2009 1(4):623-630. Berry, L. J., Haynes, N. M. and Darcy, P. K. Generation of chimeric T cell receptor transgenes and their efficient expression in primary mouse T lymphocytes. Methods Mol Biol. (in press). Berry, L. J., Moeller, M. and Darcy, P. K. Adoptive Immunotherapy for cancer: the next generation of gene-engineered immune cells. Tissue Antigens (in press).

Patents

United States Patent Application #20030026790: Activated dual specificity lymphocytes and their methods of use. Filed March 9, 2001. Patrick Hwu, Michael H. Kershaw, Steven A. Rosenberg, National Cancer Institute, Bethesda, Maryland, USA. PCT/AU2005/001873: Methods and Compositions for Adoptive Immunotherapy. Phillip Darcy, Mark Smyth, Michael Kershaw and Joseph Trapani. Filed November 2005. Peter MacCallum Cancer Centre, Melbourne, Australia. PCT /AU2005/001873: “Methods and Compositions for Adoptive Immunotherapy” Inventors: Phillip Darcy, Mark Smyth, Michael Kershaw and Joseph Trapani. Filed November 2005. Peter MacCallum Cancer Centre, Melbourne, Australia.